Shares of Akzo Nobel slid after the drug developer announced mixed results in a Phase III trial of asenapine for schizophrenia. The drug's performance in another half of the study devoted to acute mania associated with bipolar disorder was positive. But analysts quickly seized on the uncertain results for the drug in schizophrenia, noting that Akzo needs to clearly distinguish the drug from others in the field.
- read the report on Akzo from MarketWatch